PrecisionLife offers analytics and resource support to COVID-19 coronavirus research community
- Identify the complex genetic factors associated with patients’ different disease severity and outcomes
- Understanding risk factors such as smoking, gender, ethnicity, blood group and underlying health conditions
- Developing tests to identify whether people are at high- / low-risk for serious forms of the disease
- Informing the hunt for existing drugs that will be effective for given patient sub-groups, especially those at risk of late-stage disease
- Identification of novel drugs targets especially for more serious late-stage disease
To be effective, the precisionlife tools require data from a minimum of several hundred COVID-19 patients, ideally including genotype/whole genome sequence with additional data including disease severity, co-morbidities, and epidemiological/phenotype information such as blood group, smoking, gender, ethnicity etc. The methods work hypothesis-free and do not require training.
The precisionlife platform has been validated on over 20 complex disease studies and with disease specialists, development partners and in pre-clinical assays/models. Several of these studies have focused on respiratory and immune response/auto-immune diseases.
PrecisionLife believes that its tools will be particularly helpful in analyzing the COVID-19 patient datasets currently being generated, and would welcome approaches from relevant parties, both in the UK and further afield.For more information, please see www.precisionlife.com, or email firstname.lastname@example.org. PrecisionLife Ltd started in 2015, built on a shared vision to bring a new level of analytical capability to computational biology, genomic medicine and healthcare. Its precisionlife platform is built on over 30 years’ experience in delivering new technologies and products to enable the discovery of richer and more useful links between patients, disease, targets and drugs. Headquartered in the UK, precisionlife also has operations in the US, Denmark and Poland.